Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Benzinga Newsdesk www.benzinga.com Positive 64.1%

Neg 0% Neu 0% Pos 64.1%

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $700 to $740.